Psychedelic substances, such as LSD and psilocybin mushrooms, have long been touted as holding promise for treating various mental health conditions, and the past decade has seen another round of enthusiasm for this hope. Although the clinical research (and associated media reports) on these substances continues to grow, what receives less attention is the changing policy landscape for some psychedelics in the United States. Despite the federal prohibition on supply and possession—outside